This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

Concomitant Use of SPRAVATO with Cognitive Behavioral Therapy or Psychotherapy

Last Updated: 10/28/2024

Summary

  • Across the SPRAVATO phase 3 studies in treatment-resistant depression, patients receiving psychotherapy before entering the trials (including cognitive behavioral therapy [CBT]) could continue receiving psychotherapy during the trials.1
    • CBT must have been ongoing for the last 3 months prior to the screening/prospective, observational phase. Except for new CBT, which was prohibited, new psychotherapy was allowed during these studies.1
    • During the phase 3 program, one study removed the restriction related to CBT and allowed for all previous forms of psychotherapy to be continued or newly initiated during the study.2
  • The clinical trial program in major depressive disorder with suicidal ideation and intent provided all patients with standard-of-care treatment, which included psychotherapy.3

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 20 September 2024.

References

1 Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428-438.  
2 Data on File. Esketamine. Protocol ESKETINTRD3004; Phase 3 Amendment.  Janssen Research & Development, LLC; 2016.  
3 Ionescu DF, Fu DJ, Qiu X, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol. 2021;24(1):22-31.